Research Signal – Source date 2025-08-19
Cells called senescent have stopped dividing, but they can remain active in tissues. Some release signals that affect neighboring cells; others resist the usual routes to cell death. A review published on August 19, 2025, asks whether those traits help explain why some drugs developed against tumors might also clear senescent cells.
The review organizes findings around features shared by senescent and tumor cells, including survival signaling, altered metabolism, secretions, epigenetic changes and immune surveillance. Its contribution is a way to think about drug discovery, not a report that a cancer drug has become a proven treatment for aging-related disease. The key question is whether a compound can act selectively in a particular senescent-cell setting.
A cell can stop dividing and still resist death
Cellular senescence is not simply a cell switching off. A senescent cell has stopped dividing, yet may retain signals that help it survive. Tumor cells can also resist apoptosis—the process by which a cell undergoes programmed death—making this overlap a useful starting point for examining possible drug targets.
The review highlights proteins in the Bcl-2 family, including Bcl-2, Bcl-xL and Bcl-w. These proteins help restrain cell death. The review describes elevated levels of some of them in senescent cells, alongside evidence that senescent cells can be harder to push into apoptosis than younger cells. In one cited setting, senescent cells showed a 10–20-fold reduction in apoptosis under UV-induced stress, with Bcl-xL increasing rather than decreasing.
That resistance creates a possible vulnerability: a drug that blocks survival proteins might allow some senescent cells to die. The review discusses BH3 mimetics such as navitoclax, originally developed to inhibit Bcl-2-family proteins in cancer research, as compounds investigated for senolytic activity. Senolytic means intended to clear senescent cells. The proposed connection is a shared survival pathway; whether it produces selective clearance depends on the compound and the cells involved.
Two ways researchers are testing survival pathways
The review’s examples include drugs aimed directly at anti-apoptotic proteins and compounds that affect the p53–MDM2 interaction. p53 can promote cell-death responses, while MDM2 is described in the review as a negative regulator of p53. Compounds that interfere with their interaction are therefore being explored as another way to shift survival toward apoptosis.
For example, the review cites RG-7112, an MDM2 inhibitor with antitumor activity and clinical-trial history in hematologic tumors, as having shown senolytic activity in senescent intervertebral disc cells. It also describes BI01 as reducing senescent cells and promoting muscle remodeling in aged mice. These are different compounds, cell settings and study types; together they illustrate a drug-discovery strategy, not a single established treatment effect.
Changing a cell’s signals is not the same as removing it
Senescent cells can release a mix of proteins and signaling molecules known as the senescence-associated secretory phenotype, or SASP. These secretions can influence inflammation and tissue regeneration around the cells. Tumor cells also release signals—including cytokines and growth factors—that can shape their local environment.
A drug may alter those signals without killing the cell that produces them. The review describes mTOR inhibitors such as rapamycin as reducing some SASP-related signals, with effects relevant to both tumor biology and aging-related processes. This is a different possible outcome from senolysis: dampening a cell’s secretory activity may change its effects on neighboring tissue, while clearance means eliminating the cell itself.
Immune-assisted clearance is another route discussed in the review. It describes evidence that programmed cell death protein 1 antibodies can help activated CD8+ T cells clear ligand-positive senescent cells. This adds an immune pathway to the drug-discovery picture, but does not mean that an approach used against tumors will reliably remove senescent cells in other tissues.
The same epigenetic target can lead to different outcomes
Epigenetic changes affect how genes are regulated. They can help maintain a cell’s state without changing the DNA sequence itself, and they are another area where senescent and tumor cells may share features. Yet targeting an epigenetic regulator does not guarantee a consistent direction of effect.
The review notes that histone deacetylase inhibitors can induce senescence in some contexts. It also describes panobinostat as reducing chemotherapy-induced senescent tumor cells in a different setting, by lowering Bcl-xL expression and increasing histone H3 acetylation. The same broad class of target can therefore be associated with inducing senescence in one context and clearing senescent tumor cells in another.
That variation matters because the intended target is a cell state, not simply a disease label. A compound’s effect can depend on which cells have become senescent, what prompted that state and the surrounding biological conditions. A promising mechanism in one model cannot by itself show that the same drug will safely clear harmful senescent cells across tissues.
Trial listings are not proof of benefit
The review brings together examples from mechanistic studies, cell models, animal research and clinical trials. Those forms of evidence answer different questions. A laboratory result can point to a mechanism worth investigating; an animal example can show an effect in that model; a clinical-trial listing shows that human investigation exists.
The review lists dasatinib plus quercetin among combinations in clinical trials across several settings, including aging-related conditions and cancers. That listing is not evidence by itself that the combination benefits patients with any particular condition. Nor does the review’s collection of trials establish a single treatment outcome or a general clinical role for senolytic drugs.
The practical challenge is selectivity. A candidate would need to remove the intended senescent cells while avoiding unacceptable effects on other cells, and its safety and clinical benefit would need to be demonstrated in the relevant disease setting. Shared biology offers starting points for that work, while the variety of examples cautions against treating “senescent cell” as one uniform target.
What more precise cell clearing could mean for age-related disease
If researchers can identify harmful senescent cells in a particular disease and selectively clear them, future treatments might help preserve tissue function by reducing the cells’ disruptive presence. That possibility depends on finding the right cells and showing that clearance is selective, safe and clinically beneficial. The review offers a way to search for candidate mechanisms; it does not establish that those conditions have been met.
Key Sources
- Primary source: Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery.
DOI or Journal Page · Review or Meta-Analysis · 2025-08-19
Keep exploring